Johnson & Johnson Reports 2007 Third-Quarter Results: Sales of $15.0 Billion Increased 12.7%; EPS was $.88, Including Special Charges; Excluding Special Charges, EPS was $1.06 *

NEW BRUNSWICK, N.J., October 16, 2007 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced third-quarter sales of $15.0 billion, an increase of 12.7% as compared to the third quarter of 2006. Operational growth was 9.7% and currency contributed 3.0%. Domestic sales were up 5.8%, while international sales increased 21.5%, reflecting operational growth of 14.7% and a positive currency impact of 6.8%. On a pro-forma basis, including the net impact of the acquisition of Pfizer Consumer Healthcare in both periods, worldwide sales increased 2.4% operationally.

Net earnings and diluted earnings per share for the third quarter of 2007 were $2.5 billion and $.88, representing decreases of 7.7% and 6.4%, respectively, compared to the same period in 2006. Net earnings for the third quarter included an after-tax restructuring charge of $528 million associated with the cost improvement program previously announced on July 31st. Prior- year third-quarter net earnings included after-tax in-process research and development charges of $115 million associated with the acquisitions of Ensure Medical, Inc. and Colbar LifeScience Ltd. Excluding the impact of these charges, net earnings for the current quarter were $3.1 billion and diluted earnings per share were $1.06, representing increases of 7.0% and 8.2%, respectively, as compared to the same period in 2006.* The Company increased its earnings guidance for full-year 2007, which excludes the impact of in- process research and development charges, restructuring charges or other special items, to between $4.10 and $4.13 per share.

"We continue to deliver solid earnings while investing in the future growth of our business," said William C. Weldon, Chairman and Chief Executive Officer. "Our broad base enables us to pursue opportunities while managing through pressures in certain markets."

Worldwide Medical Devices and Diagnostics sales of $5.2 billion for the third quarter represented a 6.0% increase over the prior year with operational growth of 3.0% and a positive impact from currency of 3.0%. Domestic sales increased 2.4%, while international sales increased 9.8% (3.7% from operations and 6.1% from currency).

Primary contributors to the operational growth included Vistakon's disposable contact lenses; LifeScan's blood glucose monitoring and insulin delivery products; DePuy's orthopaedic joint reconstruction and sports medicine products; Ethicon Endo-Surgery's minimally invasive products; and Ortho-Clinical Diagnostics' professional diagnostic products. Also contributing to the results was strong growth in Biosense Webster's electrophysiology business and in Ethicon's wound care and women's health businesses. Growth was impacted by lower sales of drug-eluting stents in our Cordis franchise primarily due to a decline in the market versus the prior year.

During the quarter, the Company received approval from the U.S. Food and Drug Administration (FDA) for the REALIZE Adjustable Gastric Band, a surgical implant for the treatment of morbid obesity. The FDA also approved the GENESEARCH Breast Lymph Node Assay, which is the first intra-operative and gene-based test to detect the spread of breast cancer into the lymph nodes.

Worldwide Pharmaceutical sales of $6.1 billion for the third quarter represented an increase over the prior year of 3.7% with operational growth of 1.2% and a positive impact from currency of 2.5%. Domestic sales decreased 2.0%, while international sales increased 14.4% (7.2% from operations and 7.2% from currency).

Sales growth reflects the strong performance of TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches; our antipsychotic franchise, which includes RISPERDAL, RISPERDAL CONSTA and INVEGA; and REMICADE, a biologic approved for the treatment of a number of immune mediated inflammatory diseases. Growth was impacted by lower sales of PROCRIT, a product for the treatment of anemia, primarily due to a decline in the market. This market decline is related to a labeling change made this past March and a decision memorandum issued by the Centers for Medicare & Medicaid Services under its national coverage analysis process.

In October, the Company received approval from the FDA for DORIBAX (doripenem for injection) as a new treatment for complicated intra-abdominal and complicated urinary tract infections, including pyelonephritis. During the quarter, the Company filed a new drug application in both the U.S. and Europe for TMC125 (etravirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral agents as a treatment for people infected with HIV-1.

Worldwide Consumer segment sales of $3.6 billion for the third quarter represented a 47.5% increase over the prior year with operational growth of 43.4% and a positive impact from currency of 4.1%. Domestic sales increased 39.8%, while international sales increased 54.2% (46.5% from operations and 7.7% from currency). On a pro-forma basis, including the net impact of the acquisition of Pfizer Consumer Healthcare in both periods, worldwide sales for the Consumer segment increased 3.5% operationally.

Sales growth in the combined business reflects the strong performance of the LISTERINE antiseptic mouthrinse and the launch of whitening products; the skin care lines of AVEENO, CLEAN & CLEAR, and NEUTROGENA; McNeil Nutritional's SPLENDA sweetener; and Baby and Kids Care products. In October, the Company announced it was voluntarily withdrawing certain infants' cough and cold products from the market. An assessment of available data on the use of pediatric cough and cold medicines identified rare instances of misuse leading to overdose, particularly in infants under 2 years of age. When used as directed, these medicines are generally recognized as safe and effective.

Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 250 Johnson & Johnson operating companies employ approximately 120,000 men and women in 57 countries and sell products throughout the world.

    * Net earnings and diluted earnings per share excluding after-tax in-

      process research and development charges and restructuring charges are

      non-GAAP financial measures and should not be considered replacements

      for GAAP results. For a reconciliation of these non-GAAP financial

      measures to the most directly comparable GAAP financial measures, see

      the accompanying tables to this release.


NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Daylight Time. A simultaneous webcast of the call for interested investors and others may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at http://www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at http://www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward- looking statements as a result of new information or future events or developments.)



    Johnson & Johnson and Subsidiaries

    Supplementary Sales Data


    (Unaudited; Dollars in Millions)                  THIRD QUARTER

                                                               Percent

                                                               Change

                                                               Operat

                                           2007     2006  Total -ions Currency

    Sales to customers

    by segment of business

    Consumer

        U.S.                               $1,591   1,138  39.8 %  39.8     -

        International                       2,032   1,318  54.2    46.5   7.7

                                            3,623   2,456  47.5    43.4   4.1

    Pharmaceutical

        U.S.                                3,765   3,841  (2.0)   (2.0)    -

        International                       2,334   2,040  14.4     7.2   7.2

                                            6,099   5,881   3.7     1.2   2.5

    Med Devices & Diagnostics

        U.S.                                2,569   2,509   2.4     2.4     -

        International                       2,679   2,441   9.8     3.7   6.1

                                            5,248   4,950   6.0     3.0   3.0


    U.S.                                    7,925   7,488   5.8     5.8     -

    International                           7,045   5,799  21.5    14.7   6.8

    Worldwide                             $14,970  13,287  12.7 %   9.7   3.0



    (Unaudited; Dollars in Millions)                   NINE MONTHS

                                                               Percent

                                                               Change

                                                               Operat

                                           2007     2006  Total -ions Currency

    Sales to customers by

    segment of business

    Consumer

        U.S.                               $4,782   3,391  41.0 %  41.0     -

        International                       5,901   3,818  54.6    48.1   6.5

                                           10,683   7,209  48.2    44.8   3.4

    Pharmaceutical

        U.S.                               11,659  11,224   3.9     3.9     -

        International                       6,810   6,093  11.8     5.6   6.2

                                           18,469  17,317   6.7     4.5   2.2

    Med Devices & Diagnostics

        U.S.                                7,772   7,619   2.0     2.0     -

        International                       8,214   7,497   9.6     4.3   5.3

                                           15,986  15,116   5.8     3.2   2.6


    U.S.                                   24,213  22,234   8.9     8.9     -

    International                          20,925  17,408  20.2    14.3   5.9

    Worldwide                             $45,138  39,642  13.9 %  11.3   2.6




    Johnson & Johnson and Subsidiaries

    Supplementary Sales Data


    (Unaudited; Dollars in Millions)                 THIRD QUARTER

                                                               Percent

                                                               Change

                                                               Operat

                                           2007     2006  Total -ions Currency

    Sales to customers

    by geographic area

    U.S.                                   $7,925   7,488   5.8 %   5.8    -


    Europe                                  3,765   3,098  21.5    13.3   8.2

    Western Hemisphere excluding U.S.       1,195     901  32.6    24.9   7.7

    Asia-Pacific, Africa                    2,085   1,800  15.8    11.8   4.0

    International                           7,045   5,799  21.5    14.7   6.8


    Worldwide                             $14,970  13,287  12.7 %   9.7   3.0



    (Unaudited; Dollars in Millions)                  NINE MONTHS

                                                               Percent

                                                               Change

                                                               Operat

                                           2007     2006  Total -ions Currency

    Sales to customers

    by geographic area

    U.S.                                  $24,213  22,234   8.9 %   8.9     -


    Europe                                 11,485   9,464  21.4    13.1   8.3

    Western Hemisphere excluding U.S.       3,372   2,599  29.7    25.2   4.5

    Asia-Pacific, Africa                    6,068   5,345  13.5    11.2   2.3

    International                          20,925  17,408  20.2    14.3   5.9


    Worldwide                             $45,138  39,642  13.9 %  11.3   2.6




    Johnson & Johnson and Subsidiaries

    Condensed Consolidated Statement of Earnings


    (Unaudited; in Millions

    Except Per Share Figures)                    THIRD QUARTER


                                        2007               2006

                                             Percent         Percent  Percent

                                               to              to    Increase

                                   Amount     Sales   Amount  Sales (Decrease)

    Sales to customers            $14,970     100.0  $13,287     100.0   12.7

    Cost of products sold           4,274      28.5    3,650      27.5   17.1

    Selling, marketing and

     administrative expenses        4,899      32.7    4,291      32.3   14.2

    Research expense                1,834      12.3    1,719      12.9    6.7

    In-process research &

     development (IPR&D)                -         -      115       0.9

    Restructuring expense             745       5.0        -         -

    Interest (income)expense, net     (52)     (0.3)    (194)     (1.5)

    Other (income)expense, net          2         -       45       0.3

    Earnings before provision for

     taxes on income                3,268      21.8    3,661      27.6  (10.7)

    Provision for taxes on income     720       4.8      901       6.8  (20.1)

    Net earnings                   $2,548      17.0   $2,760      20.8   (7.7)


    Net earnings per share

     (Diluted)                      $0.88              $0.94             (6.4)


    Average shares outstanding

     (Diluted)                    2,912.9            2,948.1


    Effective tax rate               22.0 %             24.6 %


    Adjusted earnings before

     provision for taxes and net

     earnings

         Earnings before

          provision for taxes on

          income                   $4,013 (1)  26.8   $3,776 (2)  28.4    6.3

         Net earnings              $3,076 (1)  20.5   $2,875 (2)  21.6    7.0

         Net earnings per share

          (Diluted)                 $1.06 (1)          $0.98 (2)          8.2

         Effective tax rate         23.3%              23.9%


    (1) The difference between as reported earnings and as adjusted earnings

        before provision for taxes on income, net earnings and net earnings

        per share (diluted) is the exclusion of the restructuring expense of

        $745 million, $528 million and $0.18 per share, respectively.


    (2) The difference between as reported earnings and as adjusted earnings

        before provision for taxes on income, net earnings and net earnings

        per share (diluted) is the exclusion of IPR&D of $115 million with no

        tax benefit and $0.04 per share, respectively.




    Johnson & Johnson and Subsidiaries

    Condensed Consolidated Statement of Earnings


    (Unaudited; in Millions Except

    Per Share Figures)                            NINE MONTHS


                                             Percent         Percent  Percent

                                               to              to    Increase

                                   Amount     Sales   Amount  Sales (Decrease)

    Sales to customers             $45,138     100.0  $39,642     100.0  13.9

    Cost of products sold           13,017      28.8   11,050      27.9  17.8

    Selling, marketing and

     administrative expenses        14,730      32.6   12,737      32.1  15.6

    Research expense                 5,352      11.9    5,079      12.8   5.4

    In-process research &

     development (IPR&D)               807       1.8      239       0.6

    Restructuring expense              745       1.7        -         -

    Interest (income)expense, net     (121)     (0.3)    (571)     (1.4)

    Other (income)expense, net        (343)     (0.8)    (771)     (2.0)

    Earnings before provision for

     taxes on income                10,951      24.3   11,879      30.0  (7.8)

    Provision for taxes on income    2,749       6.1    2,994       7.6  (8.2)

    Net earnings                    $8,202      18.2   $8,885      22.4  (7.7)


    Net earnings per share

     (Diluted)                       $2.81              $2.99            (6.0)


    Average shares outstanding

     (Diluted)                     2,919.3            2,971.3


    Effective tax rate                25.1 %             25.2 %


    Adjusted earnings before

     provision for taxes and net

     earnings

         Earnings before provision

          for taxes on income      $12,503 (1)  27.7  $11,496 (2)  29.0   8.8

         Net earnings               $9,537 (1)  21.1   $8,748 (2)  22.1   9.0

         Net earnings per share

          (Diluted)                  $3.27 (1)          $2.95 (2)        10.8

         Effective tax rate          23.7%              23.9%


    (1) The difference between as reported earnings and as adjusted earnings

        before provision for taxes on income, net earnings and net earnings

        per share (diluted) is the exclusion of  IPR&D of $807 million with no

        tax benefit and $0.28 per share respectively, and the exclusion of the

        restructuring expense of $745 million, $528 million and $0.18 per

        share, respectively.


    (2) The difference between as reported earnings and as adjusted earnings

        before provision for taxes on income, net earnings and net earnings

        per share (diluted) is the exclusion of the Guidant acquisition

        termination fee of $622 million, $368 million and $0.12 per share,

        respectively, and the exclusion of  IPR&D of $239 million, $231

        million and $0.08 per share, respectively.




                       REPORTED SALES vs. PRIOR PERIOD

                                     $MM


                                            CURRENT QUARTER

                                                         % Change

                             3Q 2007 3Q 2006  Reported Operational(1) Currency

    PHARMACEUTICAL SEGMENT (2)


    ACIPHEX/PARIET

    US                           159     146     8.4%        8.4%            -

    Intl                         179     161    11.6%        4.0%         7.6%

    WW                           338     307    10.1%        6.1%         4.0%


    Anti-Psychotics (3)

    US                           674     635     6.3%        6.3%            -

    Intl                         488     433    12.8%        5.6%         7.2%

    WW                         1,162   1,068     8.9%        6.0%         2.9%


    CONCERTA

    US                           177     179    -1.2%       -1.2%            -

    Intl                          54      41    34.0%       24.8%         9.2%

    WW                           231     220     5.3%        3.6%         1.7%


    DURAGESIC

    US                           107     138   -23.0%      -23.0%            -

    Intl                         202     204    -0.7%       -6.5%         5.8%

    WW                           309     342    -9.7%      -13.2%         3.5%


    EPREX/PROCRIT

    US                           380     522   -27.1%      -27.1%            -

    Intl                         302     276     9.0%        1.0%         8.0%

    WW                           682     798   -14.6%      -17.4%         2.8%


    Hormonal Contraceptives

    US                           166     210   -21.2%      -21.2%            -

    Intl                          67      60    11.9%        4.1%         7.8%

    WW                           233     270   -13.9%      -15.6%         1.7%


    LEVAQUIN

    US                           351     341     3.1%        3.1%            -

    Intl                          15       9    65.0%       61.1%         3.9%

    WW                           366     350     4.6%        4.5%         0.1%


    REMICADE

    US                           648     602     7.5%        7.5%            -

    Intl                         171     174    -1.4%       -1.4%            -

    WW                           819     776     5.5%        5.5%            -


    TOPAMAX

    US                           498     435    14.4%       14.4%            -

    Intl                         115      98    17.5%        9.7%         7.8%

    WW                           613     533    15.0%       13.6%         1.4%



                                              YEAR TO DATE

                                                         % Change

                             3Q 2007 3Q 2006  Reported Operational(1) Currency

    PHARMACEUTICAL SEGMENT (2)


    ACIPHEX/PARIET

    US                           479     438     9.3%        9.3%            -

    Intl                         531     483     9.9%        3.4%         6.5%

    WW                         1,010     921     9.7%        6.3%         3.4%


    Anti-Psychotics (3)

    US                         2,037   1,788    13.9%       13.9%            -

    Intl                       1,440   1,334     7.9%        1.8%         6.1%

    WW                         3,477   3,122    11.4%        8.8%         2.6%


    CONCERTA

    US                           576     547     5.3%        5.3%            -

    Intl                         163     125    30.5%       22.4%         8.1%

    WW                           739     672    10.0%        8.5%         1.5%


    DURAGESIC

    US                           319     369   -13.8%      -13.8%            -

    Intl                         581     633    -8.2%      -13.2%         5.0%

    WW                           900   1,002   -10.2%      -13.4%         3.2%


    EPREX/PROCRIT

    US                         1,359   1,573   -13.6%      -13.6%            -

    Intl                         898     819     9.6%        2.2%         7.4%

    WW                         2,257   2,392    -5.6%       -8.1%         2.5%


    Hormonal Contraceptives

    US                           516     597   -13.7%      -13.7%            -

    Intl                         194     175    11.3%        5.0%         6.3%

    WW                           710     772    -8.0%       -9.4%         1.4%


    LEVAQUIN

    US                         1,153   1,063     8.5%        8.5%            -

    Intl                          44      29    52.3%       51.2%         1.1%

    WW                         1,197   1,092     9.6%        9.6%         0.0%


    REMICADE

    US                         1,873   1,763     6.3%        6.3%            -

    Intl                         546     470    16.1%       16.1%         0.0%

    WW                         2,419   2,233     8.3%        8.3%         0.0%


    TOPAMAX

    US                         1,471   1,200    22.5%       22.5%            -

    Intl                         330     298    10.9%        4.0%         6.9%

    WW                         1,801   1,498    20.2%       18.8%         1.4%


     (1) Operational growth excludes the effect of currency

     (2) Select areas (unaudited)

     (3) Includes Risperdal, Risperdal Consta & Invega




                       REPORTED SALES vs. PRIOR PERIOD

                                     $MM


                                            CURRENT QUARTER

                                                         % Change

                             3Q 2007 3Q 2006 Reported  Operational(1) Currency

    MEDICAL DEVICES AND DIAGNOSTICS (2)


    Cordis

    US                           373     502   -25.6%      -25.6%            -

    Intl                         404     481   -16.3%      -20.7%         4.4%

    WW                           777     983   -21.0%      -23.1%         2.1%


    DePuy

    US                           636     605     5.2%        5.2%            -

    Intl                         450     366    22.9%       14.6%         8.3%

    WW                         1,086     971    11.9%        8.8%         3.1%


    Ethicon

    US                           349     326     7.2%        7.2%            -

    Intl                         528     470    12.1%        4.7%         7.4%

    WW                           877     796    10.1%        5.7%         4.4%


    Ethicon Endo-Surgery

    US                           440     416     5.8%        5.8%            -

    Intl                         482     409    17.7%       10.9%         6.8%

    WW                           922     825    11.7%        8.3%         3.4%


    LifeScan

    US                           321     278    15.3%       15.3%            -

    Intl                         264     227    16.8%        9.0%         7.8%

    WW                           585     505    16.0%       12.5%         3.5%


    Ortho-Clinical Diagnostics

    US                           219     184    18.7%       18.7%            -

    Intl                         185     176     5.4%       -0.2%         5.6%

    WW                           404     360    12.2%        9.5%         2.7%


    Total Vision Care

    US                           214     185    15.1%       15.1%            -

    Intl                         363     308    18.5%       15.7%         2.8%

    WW                           577     493    17.2%       15.5%         1.7%



                                              YEAR TO DATE

                                                         % Change

                             3Q 2007 3Q 2006 Reported  Operational(1) Currency

    MEDICAL DEVICES AND DIAGNOSTICS (2)


    Cordis

    US                         1,194   1,569   -23.9%      -23.9%            -

    Intl                       1,363   1,557   -12.5%      -15.8%         3.3%

    WW                         2,557   3,126   -18.2%      -19.9%         1.7%


    DePuy

    US                         1,977   1,892     4.5%        4.5%            -

    Intl                       1,401   1,153    21.5%       13.9%         7.6%

    WW                         3,378   3,045    10.9%        8.0%         2.9%


    Ethicon

    US                         1,043     943    10.6%       10.6%            -

    Intl                       1,605   1,443    11.2%        4.8%         6.4%

    WW                         2,648   2,386    11.0%        7.1%         3.9%


    Ethicon Endo-Surgery

    US                         1,311   1,212     8.2%        8.2%            -

    Intl                       1,459   1,264    15.4%        9.4%         6.0%

    WW                         2,770   2,476    11.9%        8.9%         3.0%


    LifeScan

    US                           923     857     7.7%        7.7%            -

    Intl                         807     675    19.6%       12.5%         7.1%

    WW                         1,730   1,532    13.0%        9.9%         3.1%


    Ortho-Clinical Diagnostics

    US                           653     568    14.9%       14.9%            -

    Intl                         550     530     3.7%       -1.2%         4.9%

    WW                         1,203   1,098     9.5%        7.2%         2.3%


    Total Vision Care

    US                           622     541    15.0%       15.0%            -

    Intl                       1,021     867    17.8%       16.1%         1.7%

    WW                         1,643   1,408    16.7%       15.7%         1.0%


     (1) Operational growth excludes the effect of currency

     (2) Select areas (unaudited)




                       REPORTED SALES vs. PRIOR PERIOD

                                     $MM


                                                 CURRENT QUARTER

                                                         % Change

                             3Q 2007 3Q 2006  Reported Operational(1) Currency


    CONSUMER SEGMENT (2) (3)


    Beauty Care

    US                           311     265    17.2%       17.2%            -

    Intl                         426     370    15.1%        7.9%         7.2%

    WW                           737     635    16.0%       11.8%         4.2%


    Baby & Kids Care

    US                           113     102    10.3%       10.3%            -

    Intl                         398     349    14.2%        6.4%         7.8%

    WW                           511     451    13.3%        7.3%         6.0%


    Oral Care (4)

    US                           211      NA       -           -             -

    Intl                         185      NA       -           -             -

    WW                           396      NA       -           -             -


    OTC/Nutritionals

    US                           653     481    36.0%       36.0%            -

    Intl                         611     218   179.9%      172.5%         7.4%

    WW                         1,264     699    80.9%       78.6%         2.3%


    Women's Health

    US                           149     151    -1.4%       -1.4%            -

    Intl                         312     281    11.2%        3.0%         8.2%

    WW                           461     432     6.8%        1.5%         5.3%



                                                YEAR TO DATE

                                                         % Change

                             3Q 2007 3Q 2006 Reported  Operational(1) Currency


    Operational (1) Currency


    CONSUMER SEGMENT (2) (3)


    Beauty Care

    US                         1,006     863    16.5%       16.5%            -

    Intl                       1,252   1,085    15.4%        9.0%         6.4%

    WW                         2,258   1,948    15.9%       12.3%         3.6%


    Baby & Kids Care

    US                           328     302     8.5%        8.5%            -

    Intl                       1,117     977    14.4%        8.0%         6.4%

    WW                         1,445   1,279    13.0%        8.1%         4.9%


    Oral Care (4)

    US                           600      NA       -           -             -

    Intl                         509      NA       -           -             -

    WW                         1,109      NA       -           -             -


    OTC/Nutritionals

    US                         1,892   1,340    41.3%       41.3%            -

    Intl                       1,835     645   184.4%      177.7%         6.7%

    WW                         3,727   1,985    87.8%       85.6%         2.2%


    Women's Health

    US                           475     448     6.1%        6.1%            -

    Intl                         870     798     9.0%        2.2%         6.8%

    WW                         1,345   1,246     8.0%        3.7%         4.3%


    (1) Operational growth excludes the effect of currency

    (2) Select areas (unaudited)

    (3) 2007 Includes sales from acquisition of PCH

    (4) Oral Care not disclosed in 2006

CONTACT: Press, Jeffrey J. Leebaw, +1-732-524-3350, +1-732-821-6007 (H),Bill Price, +1-732-524-6623, +1-732-668-3735 (M), or Investors, LouiseMehrotra, +1-732-524-6491, Stan Panasewicz, +1-732-524-2524, LesleyFishman, +1-732-524-3922, all of Johnson & Johnson

Web site: http://www.jnj.com/http://www.investor.jnj.com/

Company News On-Call: http://www.prnewswire.com/comp/467347.html/

Ticker Symbol: (NYSE:JNJ)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2007


View comments

Hide
(web5)